|
13 Nov 2020 |
Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
|
|
13 Nov 2020 |
Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association Scientific Sessions
|
|
13 Nov 2020 |
CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
|
|
13 Nov 2020 |
Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
|
|
13 Nov 2020 |
Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101
|
|
13 Nov 2020 |
Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting
|
|
13 Nov 2020 |
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly
|
|
13 Nov 2020 |
The CHMP has adopted a negative opinion for emapalumab in Europe for the treatment of primary HLH
|
|
13 Nov 2020 |
AlzeCure receives approval to start clinical Phase I trial with ACD856 in Alzheimer's disease
|
|
13 Nov 2020 |
KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors
|
|
13 Nov 2020 |
Janssen Submits Applications in U.S. and EU Seeking Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)/DARZALEX® (daratumumab) Subcutaneous (SC) Formulation in Combination With Pomalidomide and Dexamethasone for Patients With Relapsed or Re
|
|
13 Nov 2020 |
Neuronasal, Inc. Announces Completion of Pilot Study, Receives IND Clearance to Continue into Phase I Trials of mTBI Therapeutic
|
|
13 Nov 2020 |
MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic
|
|
13 Nov 2020 |
AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury
|
|
13 Nov 2020 |
Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)
|
|
13 Nov 2020 |
Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC
|
|
13 Nov 2020 |
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
|
|
13 Nov 2020 |
CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Muscle-Invasive Bladder Cancer
|
|
12 Nov 2020 |
Edgewise Therapeutics Initiates Phase 1 Clinical Trial of EDG-5506 in Becker Muscular Dystrophy
|
|
12 Nov 2020 |
Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157
|
